Assembly Biosciences Q2 revenue rises from Gilead collaboration
Overview
Assembly Biosciences Q2 revenue from Gilead collaboration rises to $9.6 mln
Net loss narrows to $10.2 mln from $11.2 mln year-over-year
Outlook
Assembly Bio projects cash to fund operations into mid-2026
Result Drivers
GILEAD COLLABORATION - Increased revenue from expanded research activities with Gilead
COSTS EASE - R&D expenses decrease largely due to a decrease in spending on ABI-6250 trials
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| -$1.33 |
|
Q2 Net Income |
| -$10.20 mln |
|
Q2 Basic EPS |
| -$1.33 |
|
Q2 Income From Operations |
| -$11.09 mln |
|
Q2 Operating Expenses |
| $20.72 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Assembly Biosciences Inc is $31.00, about 39.2% above its August 5 closing price of $18.86
Press Release: ID:nGNX9fY5cQ
